Are LMAT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies LMAT leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Stock Ratings / Health Care / LMAT / insiders

XRAY (32) KMTS (50) INSP (65) UFPT (74) ⌘ Pro Terminal →

LeMaitre Vascular Inc. (LMAT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$81.26 +0.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $81.16

LeMaitre Vascular Inc. (LMAT) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $1.85B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LMAT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LMAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, LeMaitre Vascular Inc. (NASDAQ: LMAT) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $81.26 (+0.40% 1D, market cap $1.85B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, LMAT ranks #108 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LMAT compare to XRAY and KMTS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), LMAT carries a Roarable C+ (67/100 RQD), trailing P/E of 33.8x, gross margin of 71.5%, and ROIC of 14.7%. By comparison, XRAY (DENTSPLY SIRONA Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B) and KMTS (Kestra Medical Technologies Ltd.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.77B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LMAT?

▼

Per LMAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001158895), LeMaitre Vascular Inc. generated $249.6M in revenue (+13.5% YoY), $57.7M in net income, and $81.3M in free cash flow against $615.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $81.16 (-0.12%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 32.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LMAT)Realized 20D OHLCV Swing Band: ±6.2%

Deterministic 5-Pillar Attribution (67/100 Composite)

🔍 WHY LMAT SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 32.6% FCF Margin ($81.3M FCF) & 71.5% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (27% of score)

Altman Z-Score 7.30 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$81.55+2.3% Next Q

Q2 (-2Q)

Grade B$83.40+0.5% Next Q

Q3 (-1Q)

Grade B$83.79-3% Next Q

Current

Grade C+$81.26+1.6% Hist 90D α

Trajectory: B+ (75) → C+ (67)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LMAT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, LMAT faces multiple-compression risk if 33.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 69.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($81.29) or 200D SMA ($94.42) invalidates the momentum regime and cuts Target Base ($84.55) toward Bear Floor ($65.95).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LMAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LMAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 67%NO 33%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

LMAT Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LMAT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on LMAT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LMAT Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LMAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.14%🛡️ HOLDING TREND SUPPORT

2026-11-03O $85.27H $85.27L $80.94C $81.26VOL 427.4K

RES: $86.27SUP: $78.17SMA50: $81.29SMA200: $94.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LMAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LMAT Butterfly Map → + Track LMAT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

26.1%/yr Implied 5Y Growth

vs. +13.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LMAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LMAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LMAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LMAT)

Health Care Rank #108 of 1016 ⚔️ XRAY vs LMAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LMAT vs. XRAY, KMTS, INSP, UFPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LeMaitre Vascular Inc. (LMAT) ranks #108 by composite RQD confidence (67/100, grade C+) and #270 by equity capitalization ($1.85B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. UFPT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with LMAT at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LMAT ACTIVE LeMaitre Vascular Inc.	C+	67/100	33.8x	71.5%	14.7%	+0.40%	$1.85B	Benchmark Subject
XRAY DENTSPLY SIRONA Inc.	E	32/100	—	50.0%	-11.0%	+3.88%	$1.90B	/xray-vs-lmat →
KMTS Kestra Medical Technologies Ltd.	D	50/100	—	51.4%	-35.0%	+0.40%	$1.77B	/kmts-vs-lmat →
INSP Inspire Medical Systems Inc.	C	65/100	14.2x	85.4%	6.0%	-1.31%	$1.97B	/insp-vs-lmat →
UFPT UFP Technologies Inc.	B	74/100	33.3x	28.3%	13.9%	-0.19%	$2.20B	/ufpt-vs-lmat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001158895

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LeMaitre Vascular Inc. (LMAT) reported GAAP revenue of $249.6M (+13.5% vs. FY2024 revenue of $219.9M , and +29.0% cumulative change since FY2023) , GAAP net income of $57.7M, operating cash flow of $81.3M, and free cash flow of $81.3M (+84.1% YoY). On the balance sheet, LMAT closed FY2025 with $615.7M in total assets against $0 in total debt (Altman Z-Score: 7.30, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$249.6M	$57.7M	$81.3M	$81.3M	$615.7M	—
FY2024 (FY)	2024-12-31	$219.9M	$44.0M	$44.1M	$44.1M	$551.8M	—
FY2023 (FY)	2023-12-31	$193.5M	$30.1M	$36.8M	$36.8M	—	—

3. LMAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LMAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LMAT compare to XRAY and KMTS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LMAT?

Where is LMAT trading relative to its 50-day, 200-day, and 52-week technical levels?

LMAT last traded at $81.26 (+0.40% on volume of 270,765 shares), positioning the stock -0.04% below its 50-day simple moving average ($81.29) and -13.94% below its 200-day simple moving average ($94.42). Across its 52-week range of $78.22 to $118.01, LMAT sits at the 7.6% percentile with a 14-day RSI of 46.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.2% ($76.22 to $86.30).

Direct Sub-Reports: LMAT RQD Cockpit LMAT 12M Forecast LMAT Earnings & Move LMAT Dividends & DRIP LMAT Insiders & 13F LMAT Whale Options LMAT Profit Sankey LMAT News & Why

ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LMAT — LeMaitre Vascular Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:27:13Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

LMAT scores 69 out of 100, a C+ grade with the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine at 18/20 (ROIC 14.7%; FCF yield 4.17%), Whale 13F Flow at 9/20, Insider Conviction at 15/20, Macro Regime Fit at 9/20 (Beta 1.0), and Forensic Balance Sheet at 18/20 (Altman Z 7.3; Piotroski F 8/9; Debt/Equity 0.5).

The strongest pillars are cash generation and balance sheet strength, which together account for the majority of the score. For a prospective investor, this suggests the business converts operations into free cash flow efficiently and carries low leverage. The upside driver is that these fundamentals provide a cushion if sentiment weakens. The valuation tradeoff is visible in the market data: trailing P/E of 33.8 and forward P/E of 28.4 are elevated, and the FCF yield of 4.17% is the cash return an investor receives at the current price. Pillars for institutional flow (9/20) and macro regime fit (9/20) are the weaker components, indicating less supportive ownership signals and only neutral sensitivity to market conditions. The "Watch for Breakout" label signals that the score alone does not establish a directional case; the stock's position relative to its 52-week range ($78.22 - $118.01) and the upcoming catalysts are the factors to monitor.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (LMAT) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. The profile does not provide a product description, customer base, or revenue model breakdown. Per the market data, the company reports a gross margin of 71.5%, an operating margin of 27.2%, and a net margin of 23.1%. Further detail on products and customers: —

Revenue grew from $193.5M (FY 2023) to $249.6M (FY 2025), and net income rose from $30.1M to $57.7M over the same span. Per the market data, ROIC is 14.7% and net margin is 23.1%. The Altman Z-Score is 7.3 and the Piotroski F-Score is 8/9, with a Debt/Equity of 0.5. Cash and debt figures are incomplete across periods in the source data.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Revenue rose from $193.5M to $249.6M across FY 2023–FY 2025 while FCF reached $81.3M, supported by an 18/20 cash engine pillar. With Fundamental Cash Engine at 18/20 (ROIC 14.7%, FCF yield 4.17%) and Institutional Whale Flow at 7/20, sustained execution supports upside toward the top of the $78.22 – $118.01 52-week range.
🐻 Primary Bear Case: Trailing P/E of 33.8 and an FCF yield of 4.17% leave limited valuation cushion, with institutional flow scored only 9/20 and an unresolved catheter recall flagged in the news feed. Investors must weigh 33.8x trailing P/E and 28.3x EV/EBITDA against 27.2% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), LMAT carries a macro regime beta of 1.00 and gross margin of 71.5%.

Key Question #1: What is the scope, timing, and financial impact of the catheter recall referenced in the news feed?
Key Question #2: What are the company's products, customer concentration, and revenue mix by segment?
Key Question #3: What are the FY 2023 and FY 2024 cash and debt balances, and the EPS for all reported periods?

LMAT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LeMaitre Vascular Inc. (LMAT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LMAT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026

Yahoo Finance report covering LeMaitre Vascular Inc. (LMAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

LeMaitre Vascular, Inc. (LMAT) Stock Forecasts

Yahoo Finance report covering LeMaitre Vascular Inc. (LMAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Rated "Hold" by Sell-Side Analysts

MarketBeat report covering LeMaitre Vascular Inc. (LMAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Is Catheter Recall Altering The Investment Case For LeMaitre Vascular (LMAT)?

Simply Wall St report covering LeMaitre Vascular Inc. (LMAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

LeMaitre Vascular, Inc. $LMAT Stock Bought by Copeland Capital Management LLC

MarketBeat report covering LeMaitre Vascular Inc. (LMAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

LeMaitre Vascular (LMAT) Climbs 2.92% to $83.05, Pressing Toward Upper Trading Range - Dividend Growth Stocks

https://www.dars.gov.et/ report covering LeMaitre Vascular Inc. (LMAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

30,639 LeMaitre Vascular, Inc. $LMAT Shares Purchased by Bridge City Capital LLC

MarketBeat report covering LeMaitre Vascular Inc. (LMAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST SeekingAlpha • 3d ago

Dividend Income Report: +15.25% And A Listener's Portfolio Roast

This month I tried something different on the podcast - a listener sent me one of his portfolios and asked me to roast it. Read more here.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LMAT Bull vs. Bear Conversation Board — What's Your Call at $81.26?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LMAT 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $104.41 (+29.0%)

📌 Pinned Debate

Revenue rose from $193.5M to $249.6M across FY 2023–FY 2025 while FCF reached $81.3M, supported by an 18/20 cash engine pillar.

The street is overcomplicating LeMaitre Vascular Inc. (LMAT). Revenue rose from $193.5M to $249.6M across FY 2023–FY 2025 while FCF reached $81.3M, supported by an 18/20 cash engine pillar.. With an RQD score of 67/100 (C+) and Forensic Balance Sheet at 18/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $87.42.

ArenaChamp_24 🐂 BULL

@SiliconVal_Bull Agree on the RQD 67/100 quality, though with 1.0 beta I'm scaling in with half-size at $80.94 and keeping dry powder in case we test $75.27.

RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH 🎯 Target: $67.99 (-16.0%)

Spot @ $80.94

Trailing P/E of 33.8 and an FCF yield of 4.17% leave limited valuation cushion, with institutional flow scored only 9/20 and an unresol

Sitting on the sidelines or leaning short LMAT above $80.94. Trailing P/E of 33.8 and an FCF yield of 4.17% leave limited valuation cushion, with institutional flow scored only 9/20 and an unresolved catheter recall flagged in the news feed.. Until Fundamental Cash Engine (18/20) and FCF yield (4.17%) inflect higher, upside is capped near $118.01.